Literature DB >> 11162929

Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa).

L P Lovely1, K B Appa Rao, Y Gui, B A Lessey.   

Abstract

Androgen receptors (AR) have been identified in the human endometrium, but their role in endometrial function and development towards endometrial receptivity remains poorly understood. In an effort to study the regulation and possible function in endometrial epithelium, we utilized the well-differentiated endometrial adenocarcinoma cell line, Ishikawa, as a model system. This cell line has proven to be stable, hormonally responsive, contains both estrogen and progesterone receptors, and has been shown to express endometrial proteins in a hormone responsive manner. In the present study, we demonstrate that Ishikawa cells also express AR, based on immunohistochemical staining, radioactive binding studies, RT-PCR and Northern blot analysis. The expression of AR is induced in Ishikawa cells by estrogens, similar to that reported for normal endometrium. Further, using an estrogen-responsive gene that has been characterized in this cell line, alkaline phosphatase, we show that androgens act as antiestrogens in diethylstilbestrol (DES) treated cells, inhibiting enzymatic activity in a dose-dependent manner. These data support a physiologic role for AR in the endometrium. Elevations in endometrial AR in certain clinical situations such as polycystic ovarian syndrome (PCOS) may amplify the effects of androgens on the endometrium leading to suspected defects in uterine receptivity, higher than expected infertility and high miscarriage rates observed in patients with this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11162929     DOI: 10.1016/s0960-0760(00)00127-8

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Dose- and Time-Dependent Transcriptional Response of Ishikawa Cells Exposed to Genistein.

Authors:  Jorge M Naciff; Zubin S Khambatta; Gregory J Carr; Jay P Tiesman; David W Singleton; Sohaib A Khan; George P Daston
Journal:  Toxicol Sci       Date:  2016-02-10       Impact factor: 4.849

2.  Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1.

Authors:  Emily Berry; Jennifer L Hardt; Jon Clardy; John R Lurain; J Julie Kim
Journal:  Gynecol Oncol       Date:  2008-11-28       Impact factor: 5.482

3.  Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models.

Authors:  S C Amaya; R F Savaris; C J Filipovic; J D Wise; E Hestermann; S L Young; B A Lessey
Journal:  Reprod Sci       Date:  2014-03-06       Impact factor: 3.060

4.  Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation.

Authors:  Suxia Bai; Gail Grossman; Lingwen Yuan; Bruce A Lessey; Frank S French; Steven L Young; Elizabeth M Wilson
Journal:  Mol Hum Reprod       Date:  2007-11-29       Impact factor: 4.025

5.  Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women.

Authors:  Bruce A Lessey; Wilder A Palomino; K B C Apparao; Steven L Young; Ruth A Lininger
Journal:  Reprod Biol Endocrinol       Date:  2006       Impact factor: 5.211

6.  Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome.

Authors:  Miki Ohara; Hiromi Yoshida-Komiya; Miho Ono-Okutsu; Akiko Yamaguchi-Ito; Toshifumi Takahashi; Keiya Fujimori
Journal:  Reprod Biol Endocrinol       Date:  2021-05-31       Impact factor: 5.211

7.  Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.

Authors:  A M Kamal; J N Bulmer; S B DeCruze; H F Stringfellow; P Martin-Hirsch; D K Hapangama
Journal:  Br J Cancer       Date:  2016-03-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.